| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
10x Genomics, Inc.$45.98
-1.07 (-2.27%)
0Pipeline Score Tools & Services · Pre-Clinical
Market Cap
3.01 B
EPS
-0.17
P/E Ratio
-
Value Trade
106.59 M
SEC Financials
Q1 2026Dilution Risk
Revenue
150.84 M
R&D Expenses
56.85 M
Operating CF
26.12 M
Total Assets
1.02 B
Total Liabilities
201.44 M
Equity
814.32 M
D/E Ratio
12,345
12.17 %
Week
1.89 %
1 Month
23.66 %
3 Month
43.86 %
6 Month
-85.16 %
5 Year
-56.15 %
All Time
Cash Data
Cash Position
539.85 M
Monthly Burn
-
Runway
12,345 mo
Burn Trend
StableSEC Filing
May 8, 2026
Overview
Volume
600.10 K
52 Week Range
8.31 - 26.45
% held by Insiders
10.92 %
% held by Institutions
98.51 %
Enterprise Value
2.55 B
Total Shares
116.83 M
Short %
14.37 %
Float Shares
112.74 M
Company Description
locked
Upcoming Catalyst
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
0
Pipeline Score -
Pipeline ValueValuation Signal
0
Drugs Scored—
rNPV / MCap Top 1%
Micro Cap (rank 905 of 913)
Percentile RankClinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in TXG
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
TXG Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-09-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-09-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-09-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
TXG▼ -2.3%today
10x Genomics and Lausanne University Hospital Collaborate to Advance Research in Diagnostic Applications of Single Cell and Spatial Technologies for Cancer Care
10x Genomics has partnered with Lausanne University Hospital to enhance cancer diagnostics using single cell and spatial technologies. The collaboration aims to identify biomarkers that predict treatment responses across various cancer types. This multi-year study will analyze tumor samples from patients and integrate clinical outcomes to improve personalized treatment strategies.
Read more →TXG10x Genomics to Report Second Quarter 2026 Financial Results on August 6, 2026
10x Genomics, a leader in life science technology, will report its second quarter 2026 financial results on August 6, 2026. The report will be followed by a public conference call at 1:30 PM PT to discuss the results and future outlook. The financial results will be available on the company's website prior to the call.
Read more →TXG10x Genomics and Cleveland Clinic Collaborate to Advance Research in Diagnostic Applications of Single Cell and Spatial Technologies in Patients with Bladder Cancer
10x Genomics has partnered with Cleveland Clinic to enhance diagnostic research for bladder cancer. This multi-year collaboration will utilize 10x's advanced platforms to analyze tumor samples from patients undergoing new therapies. The goal is to identify biomarkers that predict patient responses, improving treatment personalization in oncology.
Read more →TXG10x Genomics Acquires Proteintech Genomics, a Division Within Proteintech Group
10x Genomics has acquired Proteintech Genomics to enhance its proteomics capabilities. This acquisition introduces the Human Discovery Panel, which allows integrated analysis of proteins and transcriptomic profiles. The move aligns with 10x's vision of advancing multiomic approaches in biological research. The transaction is not expected to significantly impact 10x's near-term financial outlook.
Read more →TXG10x Genomics Reports First Quarter 2026 Financial Results
10x Genomics reported its first quarter 2026 financial results, showing a 3% decrease in revenue to $150.8 million. However, excluding one-time revenues from the previous year, revenue increased by 9%. The company launched Atera, a new platform for spatial whole-transcriptome analysis, and ended the quarter with $539.8 million in cash. Despite a net loss of $13.5 million, the company remains optimistic about its growth trajectory.
Read more →TXGx Genomics Reports First Quarter 2026 Financial Results
10x Genomics reported its financial results for the first quarter of 2026, revealing a revenue of $150.8 million, which is a 3% decline from the same period in 2025. Excluding a one-time revenue gain from the previous year, the company observed a 9% increase in revenue. Key developments include the launch of Atera, a novel platform, and a strategic partnership with Bioptimus to generate spatial data. Despite reduced operating expenses and a significant increase in cash reserves, the company continues to report a net loss of $13.5 million.
Read more →TXG▼ -5.5%on this news
10x Genomics to Participate in the BofA Securities 2026 Healthcare Conference
10x Genomics, a leader in single cell and spatial biology, will participate in the BofA Securities 2026 Healthcare Conference on May 13. The management team will engage in a fireside chat, which will be available via a live webcast. This event highlights the company's commitment to advancing human health through innovative research solutions.
Read more →TXG▼ -5.7%on this news· ran to -18% by day 3
10x Genomics Introduces Atera, a New Platform to Redefine How Biology is Measured and Understood
10x Genomics has launched Atera, a new platform for whole-transcriptome spatial biology analysis, offering single-cell sensitivity at scale. Debuting at the AACR Annual Meeting 2026, Atera aims to redefine biological measurement by overcoming previous limitations in spatial technologies. The platform has garnered interest from major research institutions and is expected to enhance understanding of complex biological systems.
Read more →TXG10x Genomics to Report First Quarter 2026 Financial Results on May 7, 2026
10x Genomics, a leader in single cell and spatial biology, will report its financial results for Q1 2026 on May 7, 2026. The announcement includes a public conference call for analysts and investors to discuss the results and future outlook. The financial results will be available on the company's website prior to the call.
Read more →TXG▼ -7.1%on this news
PharosAI and 10x Genomics Partner to Transform Cancer Research with AI and Spatial Biology
10x Genomics has partnered with PharosAI to develop a comprehensive multimodal cancer dataset using AI and spatial biology. This initiative, supported by UK government funding, aims to enhance early diagnosis and precision therapies. The collaboration will initially focus on breast cancer, expanding to other types, and will make datasets accessible to researchers globally.
Read more →TXG10x Genomics to Report Fourth Quarter and Full Year 2025 Financial Results on February 12, 2026
10x Genomics, a leader in single cell and spatial biology, will report its financial results for Q4 and the full year 2025 on February 12, 2026. The announcement includes a public conference call for analysts and investors to discuss the results and future outlook. The financial results will be available on the company's website prior to the call.
Read more →TXGCancer Research Institute Launches Transformative AI-Driven Immuno-Oncology Initiative Powered by 10x Genomics Technology
10x Genomics has partnered with the Cancer Research Institute to launch a multi-phase initiative aimed at advancing immuno-oncology research. The project will generate extensive single-cell and spatial data from over 20,000 samples, leveraging AI to map the immune landscape of cancer. This collaboration seeks to enhance understanding of immune responses and improve immunotherapy strategies.
Read more →TXG10x Genomics to Advance Research in Diagnostic Applications of Tumor Single Cell and Spatial Profiling
10x Genomics has partnered with Dana-Farber Cancer Institute to analyze tumor samples from patients with major solid cancers. This collaboration aims to identify biomarkers linked to treatment responses and establish a CLIA-certified laboratory for future diagnostic tests. The initiative seeks to improve precision oncology by understanding patient responses to emerging therapies.
Read more →TXG10x Genomics Launches Study to Advance Research in Blood-Based Diagnostics for Autoimmune Disease
10x Genomics has partnered with Brigham & Women's Hospital to study blood samples from patients with autoimmune diseases like rheumatoid arthritis and lupus. The research aims to identify immune signatures that correlate with disease activity and treatment responses. This initiative will involve 1,000 patients and seeks to develop a framework for clinical reports to aid in patient care.
Read more →TXGx Genomics Announces Preliminary Select Fourth Quarter and Full Year 2025 Results
10x Genomics (TXG) announced preliminary select financial results for Q4 and full year 2025, showing mixed performance. Revenue for Q4 reached approximately $166 million, reflecting an 11% sequential growth. However, there was a notable decrease in instruments revenue, down 39% year-over-year. The results are preliminary and subject to adjustments as the company finalizes its financial statements.
Read more →TXG10x Genomics to Present at the 44th Annual J.P. Morgan Healthcare Conference
10x Genomics, a leader in single cell and spatial biology, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026. The management team will participate in a fireside chat, which can be accessed via a live webcast. This event underscores the company's commitment to advancing human health through innovative research solutions.
Read more →TXGx Genomics Reports Third Quarter 2025 Financial Results
10x Genomics reported its financial results for Q3 2025, highlighting a revenue of $149 million, which marks a 2% sequential increase when excluding one-time revenues from the previous quarter. The company introduced the Xenium Protein platform, enabling advanced multiomic workflows. Despite a strong balance sheet with cash reserves of $482.1 million, the revenue reflects a decline of 2% year-over-year largely due to decreased instrument sales, and gross margins have also dropped. Looking ahead, 10x Genomics anticipates a revenue decline for Q4 2025, projecting between $154 million and $158 million.
Read more →TXGx Genomics Reports Second Quarter 2025 Financial Results
10x Genomics, Inc. reported its financial results for the second quarter of 2025, showing revenue of $172.9 million. Excluding a patent litigation settlement, revenue was $145.6 million, down 5% year-over-year. The company’s acquisition of Scale Biosciences is set to enhance its capabilities in single cell analysis. Despite current challenges in the funding environment, 10x Genomics reported a positive gross margin and cash reserves of $447.3 million.
Read more →TXGx Genomics Reports First Quarter 2025 Financial Results
10x Genomics, Inc. reported its financial results for Q1 2025, highlighting a total revenue of $154.9 million, which reflects a growth compared to the previous year when including a patent litigation settlement. However, revenue excluding this settlement saw a 2% decline due to lower instrument sales. The company is implementing cost-reduction strategies, including workforce cuts, as it faces uncertainties in funding for research. Despite these challenges, 10x Genomics announced plans to launch new products and maintain its strong balance sheet.
Read more →TXG▲ +6.8%on this news· ran to +19% by day 3
10x Genomics Secures Injunction Against Parse Biosciences' Planned ATAC Products
10x Genomics has successfully obtained a permanent injunction against Parse Biosciences, preventing them from producing ATAC and ATAC-Multiome Single Cell products. This decision, reached through a consent agreement, confirms the validity and infringement of 10x's ATAC-seq patents. The ongoing litigation regarding other gene expression products from Parse remains active, with additional patents under appeal.
Read more →TXGx Genomics Announces Preliminary Select Fourth Quarter and Full Year 2024 Results FY 2024 revenue of $611 million and Q4 2024 revenue of $165 million, representing 9% growth sequentially
10x Genomics, Inc. announced its preliminary revenue results for the fourth quarter and full year of 2024, reporting total revenue of approximately $611 million for the year and $165 million for the fourth quarter. The company experienced a sequential revenue growth of 9% in Q4, although there were declines compared to the same quarter in the previous year. Instruments revenue for the full year declined significantly by 25%, while consumables revenue increased by 3%. The firm attributed its sequential growth to increases in its services revenue, which grew by 57% year-over-year.
Read more →TXGx Genomics Reports Third Quarter 2024 Financial Results
10x Genomics, Inc. reported its third quarter financial results for 2024, revealing a slight revenue decrease of 1% year-over-year, totaling $151.7 million. The company launched several new products aimed at enhancing research efficiency and cost-effectiveness, including GEM-X Flex and Chromium Xo. Despite product innovations, the CEO noted that revenues fell short of expectations due to sales restructuring and cautious customer spending. The company has updated its full-year revenue guidance downward, now projecting between $595 million and $605 million.
Read more →TXGx Genomics Announces Preliminary Select Third Quarter 2024 Results
10x Genomics announced its preliminary select results for Q3 2024, revealing a slight revenue decline of 1% year-over-year, amounting to approximately $151.7 million. The company reported a significant drop in instruments revenue, specifically a 46% decrease, while consumables and services showed growth of 10% and 48%, respectively. Regional performance varied, with the Americas reporting an 11% decline, contrasted by increases in EMEA and APAC. The CEO acknowledged the adverse effects of recent organizational changes on instrument sales, although he expressed confidence in their long-term growth strategy.
Read more →TXG▲ +7.8%on this news· ran to +19% by day 3
x Genomics Reports Second Quarter 2024 Financial Results
10x Genomics reported a revenue of $153.1 million for Q2 2024, reflecting a 4% growth from the same quarter in the prior year. Despite a noticeable decrease in operating expenses, the company faced a net loss of $37.9 million, improved from the previous year's loss. The company has also launched the Xenium Prime 5K and received recognition for its Chromium GEM-X product from the Garvan Institute. However, full-year revenue guidance has been adjusted downward, suggesting ongoing market challenges.
Read more →TXG10x Genomics Launches 5,000-Plex Gene Panel for Xenium
10x Genomics has launched the Xenium Prime5KPan-Tissue and Pathways panel, significantly increasing the plex capacity for gene analysis. This new assay offers enhanced sensitivity and specificity, enabling researchers to explore molecular pathways and biomarkers more effectively. The product is now available for preorder and expected to ship next month.
Read more →TXG▼ -8.1%on this news
10x Genomics Reports First Quarter 2024 Financial Results
10x Genomics reported its financial results for Q1 2024, showing a revenue increase to $141 million, up 5% year-over-year. The company launched four new products, including Visium HD, which contributed to growth in the Spatial segment. However, it faced a decrease in gross margin and an increase in operating and net losses compared to the previous year. The company maintains its revenue guidance for the full year 2024, projecting growth of 8% to 12%.
Read more →TXGx Genomics Reports First Quarter 2024 Financial Results
10x Genomics, Inc. has reported its financial results for the first quarter of 2024, showing a revenue increase of 5% year-over-year, totaling $141 million. The company launched four significant new products, indicating a strong push in single cell and spatial biology technologies. However, operating losses rose to $61.5 million, primarily impacted by higher operating expenses and reduced gross margin. Despite these challenges, 10x Genomics maintains its revenue guidance for the full year, projecting growth between 8% to 12% over 2023.
Read more →TXG▼ -5.5%on this news
10x Genomics to Report First Quarter 2024 Financial Results on April 30, 2024 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that it will report financial results for the first...
10x Genomics, Inc. is scheduled to report its financial results for the first quarter of 2024 after market close on April 30, 2024. A public conference call and live webcast for analysts and investors will take place the same day at 1:30 p.m. Pacific Time. The news release with the results will be available on the company's website prior to the call. 10x Genomics focuses on advancing human health through its innovative technology solutions in single cell and spatial biology.
Read more →TXG10x Genomics Commercially Launches Visium HD Spatial Gene Expression Assay
10x Genomics has announced the commercial launch of its Visium HD Spatial Gene Expression assay. This new product allows researchers to conduct whole transcriptome analysis at single cell-scale resolution, specifically from FFPE tissue sections. The global shipments for Visium HD have already begun, marking a significant advancement in spatial biology.
Read more →TXG10x Genomics Expands Xenium Menu with Multi-Modal Cell Segmentation Kit and Immuno-Oncology Gene Panel
10x Genomics has announced the commercial launch of its Xenium multi-modal cell segmentation kit and a new Immuno-Oncology gene panel. These products aim to improve cell boundary determination and enhance research capabilities in immuno-oncology. The company plans further product launches throughout the year to meet customer needs.
Read more →TXG10x Genomics Begins Commercial Shipments of Chromium GEM-X Products
10x Genomics has commenced commercial shipments of its new GEM-X products, including the Chromium Single Cell Gene Expression 3' v4 and Chromium Single Cell Immune Profiling 5' v3. This next-generation technology architecture is designed to improve performance and reduce costs for researchers. The company anticipates that these advancements will significantly enhance single cell analysis capabilities.
Read more →TXG10x Genomics to Present at the 44th Annual TD Cowen Health Care Conference
10x Genomics, a leader in single cell and spatial biology, will participate in a fireside chat at the 44th Annual TD Cowen Health Care Conference on March 5, 2024. The event will be accessible via a live webcast, which will also be archived for later viewing. This participation highlights the company's commitment to advancing human health through innovative technology.
Read more →TXG10x Genomics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Outlook for 2024 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the fourth quarter and full year...
10x Genomics, Inc. (Nasdaq: TXG) reported an 18% revenue increase for Q4 2023 and 20% for FY 2023, driven by sales of Spatial instruments. Despite its growth, the company recorded operating losses that heightened in both quarterly and yearly comparisons. 10x Genomics also highlighted a decrease in gross margins and rising operating expenses due to in-process research and development. Looking ahead, it anticipates 8% to 12% revenue growth in 2024, maintaining a positive outlook despite some financial challenges.
Read more →TXG▲ +5.3%on this news
10x Genomics Expands Leadership in Single Cell Analysis with Launch of GEM-X Technology
10x Genomics has launched GEM-X, an advanced single cell technology that improves performance and reduces costs. This new architecture, built on an optimized microfluidic chip design, is expected to enhance research capabilities for academic and translational researchers. Pre-orders for the first two products powered by GEM-X are now open, with shipments expected in the first quarter of 2024.
Read more →TXG10x Genomics to Showcase New Cutting-Edge Technologies and Highlight Innovation Roadmap at 2024 AGBT General Meeting 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today a series of new products and technology demonstrations ...
10x Genomics, Inc. announced an array of new products and technology demonstrations to be showcased at the 2024 AGBT General Meeting in Orlando, Florida. The company is set to redefine its Visium, Xenium, and Chromium platforms with tools that enhance research capabilities in single cell and spatial biology. Noteworthy introductions include the Visium HD, which offers whole transcriptome spatial discovery at single-cell resolution, and rapid growth in the Xenium platform. A live-streamed workshop will allow global researchers to engage with new data and product offerings.
Read more →TXG10x Genomics to Report Fourth Quarter and Full Year 2023 Financial Results on February 15, 2024 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that it will report financial results for the fourth...
10x Genomics, Inc. (Nasdaq: TXG) will report its financial results for the fourth quarter and full year ended December 31, 2023, on February 15, 2024. A public conference call and live webcast for analysts and investors will take place the same day. The company, recognized for its advancements in single cell and spatial biology, intends to discuss its results, business developments, and future outlook during the call.
Read more →TXGx Genomics Announces Preliminary Fourth Quarter and Full Year 2023 Results
10x Genomics, Inc. announced preliminary results for the fourth quarter and full year 2023, reporting approximately $184 million in revenue for Q4, reflecting an 18% increase year-over-year. The full year revenue is estimated at $618.7 million, up 20% from the previous year, driven by substantial growth in instruments and services revenue. Instrument sales notably grew by 71%, with over 5,900 cumulative devices sold. Although these figures are preliminary and subject to final adjustments, they indicate a robust performance in the single-cell and spatial biology market.
Read more →TXG10x Genomics to Present at the 42nd Annual J.P. Morgan Healthcare Conference 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that members of its management team will present at...
10x Genomics, Inc. (Nasdaq: TXG) has announced that its management team will present at the 42nd Annual J.P. Morgan Healthcare Conference scheduled for January 8, 2024. Interested parties can access a live webcast of the presentation on the company’s investor website. Additionally, the webcast will be available for replay for at least 45 days after the event, reflecting the company's dedication to transparency and investor engagement.
Read more →TXG10x Genomics Launches Xenium Catalyst Network 10x Genomics, Inc., (Nasdaq: TXG), a leader in single cell and spatial biology, today announced the launch of its Xenium Catalyst Network, a global...
10x Genomics has launched the Xenium Catalyst Network, aimed at providing researchers with accelerated access to proof-of-concept data for the Xenium platform. The founding member institutions are Macrogen, K2bio, BioChain Institute, and The McDonnell Genome Institute, each bringing unique expertise to the collaboration. This initiative is anticipated to enhance the overall research capabilities and increase the reach of their genomic technologies. The company is optimistic about expanding the network with additional institutions in 2024, leveraging partnerships to foster innovative research solutions.
Read more →TXG▲ +5.8%on this newsshared move
Integrative Study Conducted by 10x Genomics Combines Single Cell, Spatial and In Situ Analyses to Investigate Tumor Invasiveness 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that Nature Communications has published a...
10x Genomics published a study in Nature Communications demonstrating the integration of their Chromium Single Cell, Visium Spatial, and Xenium In Situ platforms to analyze human breast tumor microenvironments. This comprehensive analysis revealed significant variations in tumor invasiveness and cellular composition that were previously overlooked by traditional pathological methods. The study illustrates how combining different technologies enhances the understanding of cancer biology, potentially leading to more effective diagnostic and therapeutic approaches.
Read more →TXG▲ +5.3%on this news
High Sensitivity and Specificity of the Xenium Platform from 10x Genomics Outperforms NanoString's CosMx and Vizgen's Merscope in Benchmarking Preprint 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that a new non-peer-reviewed study has independently...
10x Genomics has announced that its Xenium In Situ platform outperformed competing spatial imaging platforms, NanoString's CosMx and Vizgen's MERSCOPE, in a recent benchmarking study. The non-peer-reviewed research highlighted Xenium's superior sensitivity and specificity when analyzing 22 archival FFPE tissue samples. The platform excelled in detecting a greater number of genes and accurately identifying low-expressing genes essential for recognizing immune cell types. These findings contribute to validating the robust performance of Xenium for clinical applications and further solidify its position in the market for spatial biology tools.
Read more →TXG10x Genomics and NIH CARD to Create Comprehensive Single Cell Atlas of the Human Brain 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today a collaboration with the NIH Intramural Center for...
10x Genomics has announced a collaboration with the NIH Intramural Center for Alzheimer's and Related Dementias (NIH CARD) to develop a comprehensive single cell atlas of the human brain. This initiative focuses on understanding cellular changes in neurodegenerative disorders by analyzing over 1,000 brain samples. The collaboration aims to provide researchers with standardized data to enhance their understanding of these complex diseases. The research is expected to lead to improvements in prevention, diagnosis, and treatment of neurodegenerative conditions.
Read more →TXG▲ +5.6%on this news
10x Genomics Wins Another Patent Infringement Case Against NanoString Technologies 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that a jury in the U.S. District Court for the...
10x Genomics, Inc. announced a significant legal victory stemming from a patent infringement case against NanoString Technologies. A jury in Delaware ruled in favor of 10x, awarding over $31 million for damages and confirming the validity of seven patents that NanoString was found to willfully infringe. This ruling marks the third consecutive court decision against NanoString in just six months, solidifying 10x's position in protecting their innovations. Furthermore, 10x plans to pursue additional legal actions including ongoing royalties and a permanent injunction to prevent further infringement.
Read more →TXGOWKIN Integrates 10x Genomics Spatial Omics and Single-Cell Technologies to the MOSAIC Study OWKIN and 10x Genomics, Inc. (Nasdaq: TXG), announce they have entered into an agreement to add 10x Genomics spatial omics and single-cell...
OWKIN and 10x Genomics, Inc. have partnered to incorporate 10x's spatial omics and single-cell technologies into the MOSAIC study, a significant $50 million initiative. MOSAIC aims to create the world's largest spatial omics dataset for cancer research, consisting of 7,000 tumor samples. This collaboration is expected to enhance the analysis of tumor structures, enabling novel insights into cancer biology and patient treatment responses. Both companies express enthusiasm about the transformative potential of their combined technologies in advancing cancer care.
Read more →TXG▲ +6.4%on this newsshared move
10x Genomics Reports Third Quarter 2023 Financial Results 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the third quarter ended September ...
10x Genomics, Inc. reported its financial results for the third quarter of 2023, showing a 17% increase in revenue compared to the same period last year, driven largely by its Xenium platform. Despite the revenue growth, the company's gross margin decreased to 62%, and operating expenses rose significantly, resulting in an operating loss of $94.8 million. The company has raised its full-year revenue guidance to between $610 million and $625 million, indicating continued optimism in its financial performance. CEO Serge Saxonov highlighted the strong demand for Xenium as a key factor in their optimistic outlook.
Read more →TXG▲ +6.4%on this newsshared move
x Genomics Reports Third Quarter 2023 Financial Results
10x Genomics reported its financial results for the third quarter of 2023, highlighting a revenue increase of 17%, reaching $153.6 million. The growth was primarily driven by the strong performance of its Xenium platform. However, operating loss widened to $94.8 million, and the gross margin decreased to 62%. The company has raised its full year revenue guidance, expecting between $610 million and $625 million, reflecting positive momentum despite increased operating expenses.
Read more →TXGStudy Fueled by Xenium Analysis Sheds Light on Resistance Mechanisms in Model of Lethal Pediatric Brain Tumors 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that the 10x Xenium Analyzer was used in a study...
10x Genomics, Inc. announced that the 10x Xenium Analyzer contributed to a study published on bioRxiv which identifies radiation-resistance mechanisms in pediatric diffuse midline gliomas (DMGs). The research led by Duke University highlights the role of Atm loss in tumor response to radiation therapy. This groundbreaking study utilizes customer-generated data to advance understanding of treatment efficacy, potentially improving clinical trials and therapeutic strategies for affected patients. The findings emphasize the nuanced molecular interactions within tumor microenvironments, enabling future research in combination therapies.
Read more →TXG10x Genomics to Report Third Quarter 2023 Financial Results on November 2, 2023 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today it will report financial results for the third quarter ...
10x Genomics, Inc. (Nasdaq: TXG) announced it will publish its financial results for the third quarter of 2023 on November 2, 2023. The company will host a conference call and webcast for analysts and investors to discuss the outcomes, business developments, and future outlook. This event highlights the ongoing progress of 10x Genomics in the field of life science technology, particularly in single cell and spatial biology.
Read more →TXGx Genomics Reports Second Quarter 2023 Financial Results
10x Genomics, a leader in single cell and spatial biology, reported a strong financial performance for the second quarter of 2023, with revenue reaching $146.8 million, marking a 28% increase year-over-year. The company successfully launched new products and raised its full-year revenue guidance to between $600 million and $620 million. However, the gross margin decreased to 68% due to changes in product mix, and operating expenses increased as the company expands its operations. The net loss for the quarter was reported at $62.4 million, slightly improved from the previous year's loss.
Read more →TXGx Genomics Wins Permanent Injunction Against NanoString's CosMx Products 10x Genomics is seeking additional injunctions to protect its intellectual property
10x Genomics has won a permanent injunction against NanoString Technologies, preventing the sale of CosMx products in Germany due to patent infringement. The Munich Regional Court found that the CosMx instruments violated 10x's European patent related to in situ detection. In response, 10x is also pursuing additional injunctions in the United States and elsewhere. To assist affected researchers, 10x is launching special programs to transition them to its Xenium platform, which offers competitive advantages in the marketplace.
Read more →TXGx Genomics Reports First Quarter 2023 Financial Results
10x Genomics announced its financial results for the first quarter of 2023, reporting revenue of $134.3 million, a 17% increase from 2022. The company also highlighted strong growth in its Spatial revenue, particularly from the Xenium product launched earlier this year. However, operating losses rose, and gross margins decreased, raising concerns about profitability trends. Despite these challenges, 10x has raised its full-year revenue guidance, reflecting positive expectations for future growth.
Read more →TXGx Genomics Reports Third Quarter 2022 Financial Results
10x Genomics Reports Third Quarter 2022 Financial Results PLEASANTON, Calif. November 2, 2022 - 10x Genomics, Inc. (Nasdaq TXG) today reported financial results for the third quarter ended September 30, 2022. Revenue was $131.1 million for the third quarter, representing a 5% i
Read more →TXGx Genomics Reports Second Quarter 2022 Financial Results
10x Genomics Reports Second Quarter 2022 Financial Results PLEASANTON, Calif. August 8, 2022 - 10x Genomics, Inc. (Nasdaq TXG) today reported financial results for the second quarter ended June 30, 2022. Revenue was $114.6 million for the second quarter, representing a 1% decre
Read more →TXG▼ -7.7%on this news· ran to -23% by day 1
x Genomics Announces Preliminary Second Quarter 2022 Revenue
10x Genomics Announces Preliminary Second Quarter 2022 Revenue PLEASANTON, Calif., July 14, 2022 - 10x Genomics, Inc. (Nasdaq TXG), a life sciences leader focused on mastering biology to advance human health, today announced that its preliminary revenue is expected to be approxi
Read more →TXGx Genomics Reports First Quarter 2022 Financial Results Q1 2022 revenue growth of 8% over prior year
10x Genomics Reports First Quarter 2022 Financial Results Q1 2022 revenue growth of 8% over prior year PLEASANTON, Calif. May 4, 2022 - 10x Genomics, Inc. (Nasdaq TXG) today reported financial results for the first quarter ended March 31, 2022. Revenue was $114.5 million for t
Read more →TXGx Genomics Reports Third Quarter 2021 Financial Results Q3 2021 revenue growth of 74% over prior year and 8% over prior quarter
10x Genomics Reports Third Quarter 2021 Financial Results Q3 2021 revenue growth of 74% over prior year and 8% over prior quarter PLEASANTON, Calif. November 3, 2021 - 10x Genomics, Inc. (Nasdaq TXG) today reported financial results for the third quarter ended September 30, 202
Read more →TXG▲ +6%on this news
10x Genomics to Report Third Quarter Financial Results on November 3, 2021 10x Genomics (Nasdaq: TXG) today announced it will report financial results for the third quarter 2021 after market close on Wednesday, November 3rd, ...
PLEASANTON, Calif. , Oct. 7, 2021 /PRNewswire/ -- 10x Genomics (Nasdaq: TXG ) today announced it will report financial results for the third quarter 2021 after market close on Wednesday, November 3rd, 2021 . The company's management will webcast a corresponding conference call be
Read more →TXG10x Genomics to Present at the Morgan Stanley 19th Annual Global Healthcare Conference
10x Genomics, Inc. announced its participation in the Morgan Stanley 19th Annual Global Healthcare Conference, scheduled for September 13th. The presentation will be accessible via a live and archived webcast. The company is recognized for its innovative life science technology products, which are widely adopted in leading research institutions and pharmaceutical companies.
Read more →TXG10x Genomics to Present at the UBS Genomics 2.0 and MedTech Innovations Summit
10x Genomics, Inc. announced its participation in the UBS Genomics 2.0 and MedTech Innovations Summit scheduled for August 10th. The presentation will be accessible via a live and archived webcast. The company is recognized for its advanced life science technology and has a significant presence in global research and pharmaceutical sectors.
Read more →TXG▼ -5.2%on this newsshared move
10x Genomics Reports Second Quarter 2021 Financial Results
10x Genomics reported a strong second quarter for 2021, with revenues reaching $115.8 million, a 170% increase from the previous year. The company attributed this growth to increased consumables revenue and a reduced impact from the pandemic. Despite a significant rise in operating expenses, the gross margin improved to 96% due to a reversal of accrued royalties. The company maintains its revenue guidance for the full year, projecting $480 million to $500 million.
Read more →TXGx Genomics Reports Second Quarter 2021 Financial Results Q2 2021 revenue growth of 170% over prior year and 9% over prior quarter
10x Genomics Reports Second Quarter 2021 Financial Results Q2 2021 revenue growth of 170% over prior year and 9% over prior quarter PLEASANTON, Calif. August 4, 2021 - 10x Genomics, Inc. (Nasdaq TXG) today reported financial results for the second quarter ended June 30, 2021.
Read more →TXG10x Genomics Signs Global Patent Cross License Agreement with Bio-Rad
10x Genomics has entered a global cross-license agreement with Bio-Rad, resolving all legal disputes between the two companies. This agreement allows both firms to develop products related to single cell analysis while excluding certain technologies. The settlement highlights the strength of 10x Genomics' patent portfolio, which has been built over nearly a decade.
Read more →TXGx Genomics Signs Global Patent Cross License Agreement with Bio-Rad Agreement to Cross License Single Cell Technologies Ends all Ongoing Legal Disputes
10x Genomics Signs Global Patent Cross License Agreement with Bio-Rad Agreement to Cross License Single Cell Technologies Ends all Ongoing Legal Disputes PLEASANTON, Calif., July 27, 2021 -- 10x Genomics, Inc. (Nasdaq TXG) today announced that it has entered into a global settl
Read more →TXG▼ -6.8%on this news
10x Genomics Introduces New Chromium X Series for Single Cell Analysis
10x Genomics has launched its new Chromium X Series, a next-generation platform for single cell analysis. This series includes the Chromium X, which allows for million cell experiments at a low cost, and the Chromium iX, designed for larger experiments. The new instruments aim to facilitate extensive research in drug discovery, CRISPR screens, and biomarker identification, while maintaining compatibility with existing assays.
Read more →TXG10x Genomics Unlocks Whole Transcriptome Analysis in FFPE Tissues With New Visium Assay, Now Shipping
10x Genomics has launched its new Visium Spatial Gene Expression assay for FFPE tissues, enabling whole transcriptome analysis. This innovative product addresses the challenges posed by FFPE processing, allowing researchers to conduct unbiased studies in translational research. Institutions like the Keck School of Medicine and UPMC Hillman Cancer Center are already evaluating its potential in various fields.
Read more →TXG10x Genomics to Participate in Upcoming June Investor Conferences
10x Genomics, Inc. announced its participation in several upcoming investor conferences. The company, known for its life science technology products, aims to enhance understanding of biological systems. Their solutions have been widely adopted in top research institutions and pharmaceutical companies, showcasing their impact in the field.
Read more →TXGx Genomics Reports First Quarter 2021 Financial Results Q1 2021 revenue growth of 47% over prior year
10x Genomics Reports First Quarter 2021 Financial Results Q1 2021 revenue growth of 47% over prior year PLEASANTON, Calif. May 5, 2021 - 10x Genomics, Inc. (Nasdaq TXG) today reported financial results for the first quarter ended March 31, 2021. Revenue was $105.8 million for
Read more →TXG10x Genomics to Present at the BofA Securities 2021 Virtual Healthcare Conference
10x Genomics, Inc. announced its participation in the BofA Securities 2021 Virtual Healthcare Conference, scheduled for May 12, 2021. The company's management will present at 3:30 p.m. ET. Interested parties can access the presentation via a live and archived webcast on their website. 10x Genomics is recognized for its innovative life science technology products.
Read more →TXGx Genomics Reports Third Quarter 2020 Financial Results
10x Genomics Reports Third Quarter 2020 Financial Results PLEASANTON, Calif. November 10, 2020 - 10x Genomics, Inc. (Nasdaq TXG) today reported financial results for the third quarter ended September 30, 2020. Revenue was $71.8 million for the third quarter, representing a 17%
Read more →TXGx Genomics Advances into Emerging Field of In Situ Analysis with Two Acquisitions Signs Agreement to Acquire ReadCoor Acquires Sweden's CartaNA
10x Genomics Advances into Emerging Field of In Situ Analysis with Two Acquisitions Signs Agreement to Acquire ReadCoor Acquires Sweden's CartaNA AB PLEASANTON, Calif. October 5, 2020 - Continuing on its mission of mastering biology to advance human health, 10x Genomics, Inc.
Read more →TXGx Genomics Reports Second Quarter 2020 Financial Results
10x Genomics Reports Second Quarter 2020 Financial Results PLEASANTON, Calif. August 11, 2020 - 10x Genomics, Inc. (Nasdaq TXG) today reported financial results for the second quarter ended June 30, 2020. Revenue was $42.9 million for the second quarter, representing a 23% decr
Read more →TXGx Genomics Reports First Quarter 2020 Financial Results
10x Genomics Reports First Quarter 2020 Financial Results PLEASANTON, Calif. May 11, 2020 10x Genomics, Inc. (Nasdaq: TXG) today reported financial results for the quarter ended March 31, We are doing all we can to support our customers as they race to understand and fight the
Read more →TXGx Genomics Provides COVID-19 Business Impact Update and Response Provides Preliminary Revenue Range for the First Quarter 2020 Withdraws Prior 2020 Annual Revenue Guidance
10x Genomics Provides COVID-19 Business Impact Update and Provides Preliminary Revenue Range for the First Quarter 2020 Withdraws Prior 2020 Annual Revenue Guidance PLEASANTON, Calif. April 9, 2020 10x Genomics (Nasdaq: TXG), today provided an update on the actions it is takin
Read more →TXGx Genomics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Full Year 2020 Revenue Guidance Full year 2019 revenue growth of 68% over prior year
10x Genomics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Full Year 2020 Revenue Guidance Full year 2019 revenue growth of 68% over prior year PLEASANTON, Calif. February 18, 2020 10x Genomics, Inc. (Nasdaq: TXG), today reported financial results fo
Read more →TXGx Genomics Reports Third Quarter 2019 Financial Results and Provides 2019 Revenue Guidance Q3 2019 revenue growth of 67% over prior year period
10x Genomics Reports Third Quarter 2019 Financial Results and Provides 2019 Revenue Guidance Q3 2019 revenue growth of 67% over prior year period PLEASANTON, Calif. November 7, 2019 10x Genomics, Inc. (Nasdaq: TXG), today reported financial results for the third quarter ended
Read more →TXGx Genomics Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters Option to Purchase Additional Shares
10x Genomics Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters Option to Purchase Additional Shares PLEASANTON, Calif. September 16, 2019 10x Genomics (Nasdaq: TXG) today announced the closing of its initial public offering of 11,500,000 sha
Read more →Competitive Position
How TXG ranks across every disease it competes inCompetitive Position is a premium feature
See how TXG ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial